ASCO/EHA 2023
Welcome to the Janssen Oncology Virtual Newsroom.
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head Oncology
Janssen Research & Development, LLC
Global Therapeutic Area Head Oncology
Janssen Research & Development, LLC
Tyrone Brewer
U.S. President, Oncology
Janssen Biotech, Inc
U.S. President, Oncology
Janssen Biotech, Inc
Latest news
Abstract chart and data research
New Long-Term Data from the CHRYSALIS Study Show Median PFS Not Reached after 33.6 Months of Follow Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced NSCLC
Featured stories